SYNTHESIS AND EVALUATION OF SUBSTITUTED AND UNSUBSTITUTED 3,6- DIMETHYLQUINOXALINE-2(1H)-THIOL DERIVATIVES FOR MRSA ACTIVITY
Dharyappa Teli*, Dr. R.B. Kotnal and Sangappa Teli
When the viable solvents businesses launched penicillin, in the establishment of 19th century invented by
Alexander Fleming, a major reduce in the number of deaths caused by bacterial infections has been confirmed.
Optimists have even noticed an end to the period of bacterial diseases. However, too frequent, and frequently
improper, applications of antibiotics have resulted in the development of drug resistant bacteria such as methicillinresistant
Staphylococcus aureus (MRSA), WHO generated a list of priority pathogens to focus the development of
new antibacterial drugs against; MRSA ranked as a high priority. Unfortunately, the development of new
antibacterial drugs has progressively declined since the 1980s. In my research work novel derivatives of
Quinoxaline obtained from ortho phenylene diamine and pyruvic acid gives 3,6-methyl quinoxaline-2(1H)-one
[DR-I] it was treated with phosphorous pentasulphide gives 3,6-methyl quinoxaline-2(1H)-thiol [DR-II] which is
converted into resultant compound derivatives of 2,6-methyl-3-[(3-nitropyridin-2-yl) sulfonyl] quinoxaline (DRIIA-
IIF). All the compounds synthesized were confirmed by spectral data and evaluated for their methicillinresistant
Staphylococcus aureus (MRSA) activity Vancomycin was used as standard. The compounds DR-IIA and
DR-IID have shown good activity and remaining shows poor activity against bacteria.
Keywords: Quinoxalines, Antibacterial Activity, Vancomycin, Methicillin-Resistant Staphylococcus aureus (MRSA).
[Full Text Article]